Ardent Health Partners Inc (NYSE: ARDT) Faces Legal Challenges Amid Financial Forecasts

Font: Financial Modeling Prep  • Mar 09, 2026

• RBC Capital sets a price target of $13 for ARDT, indicating a potential increase of approximately 41.77%.
• A class action lawsuit alleges securities fraud against Ardent Health, potentially impacting investor confidence.
• Despite legal issues, ARDT's stock shows a 3.03% increase, with today's trading volume at 669,197 shares.

Ardent Health Partners Inc (NYSE: ARDT) is a healthcare company that operates a network of hospitals and healthcare facilities. The company is involved in providing a range of medical services to communities across the United States. Ardent Health competes with other healthcare providers in the industry, striving to deliver quality care and maintain financial stability.

On March 9, 2026, Ben Hendrix from RBC Capital set a price target of $13 for ARDT. At the time, the stock was priced at $9.17, suggesting a potential increase of approximately 41.77%. This optimistic outlook comes despite the current challenges the company faces, including a class action lawsuit alleging securities fraud.

Levi & Korsinsky, LLP has filed a lawsuit against Ardent Health, claiming the company made false statements or concealed information about their financial practices. The lawsuit covers the period between July 18, 2024, and November 12, 2025, and seeks to recover losses for affected investors. This legal issue could impact investor confidence and the stock's future performance.

Currently, ARDT's stock is priced at $9.17, reflecting a 3.03% increase with a change of $0.27. The stock has fluctuated today between $8.57 and $9.18. Over the past year, ARDT has seen a high of $15.48 and a low of $8.07, indicating significant volatility in its stock price.

Ardent Health has a market capitalization of approximately $1.31 billion, which reflects the total market value of its outstanding shares. Today's trading volume for ARDT is 669,197 shares, showing active investor interest. Despite the ongoing legal challenges, the company's stock performance and market activity remain noteworthy.